Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Nasopharyngeal Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancer 1Skin Neoplasms 1Non-small Lung Cancer 1Neuroendocrine Tumors 1Neoplasms 1Meningeal Carcinomatosis 1Local Advanced Non-small Cell Lung Cancer 1Liver Neoplasms 1Klatskin Tumor 1High-risk Renal Cell Carcinoma 1Gallbladder Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

lutetium Lu 177 dotatate 11Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1Surgical Procedures, Operative 1Salts 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuroendocrine Tumors × toripalimab × Clear all
NCT05167071 2025-04-27

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 1 Active not recruiting
53 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡